Protocols for Phase I
| HIC 0604001305 Wm. Kevin Kelly M.D. Open Label, Dose Escalation Trial of Oral PXD101 in patients with Advanced Solid Tumors |
| HIC 0511000860 Maysa Abu-Khalaf M.D. A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination with Abraxane (Paclitaxel protein-bound particles) in Advanced Solid Cancers |
| HIC 0705002670 Wasif Saif M.D. A Phase I, Open-Label, Non-Randomized, Dose-Finding, Safety, Tolerance, and Pharmacokinetic Study of Orally Administered S-1 in Combination with Gemcitabine in Patients with Advanced Solid Tumors |
| HIC 26316 Masoud Azodi M.D. Phase Ib Safety And Efficacy Study Of Neoadjuvant Use Of Oral Phenoxodiol In Patients With Primary Diagnosis Of Squamous Cell Carcinoma And Adenocarcinoma Of The Cervix, Vagina Or Vulva |
| HIC 0509000643 Wasif Saif M.D. A Phase I, Open-Label Study Evaluating the Pharamacokinetics of Components of S-1 in Patients with Varying Degrees of Renal Function |
| HIC 0512000905 Wasif Saif M.D. A Phase I/II, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced Pancreatic Carcinoma |
| HIC 27640 Thomas Rutherford M.D. A Randomized Placebo-Controlled Phase Ib/IIa Safety, Tolerability And Efficacy Study Of Oral Phenoxodiol In Combination With Docetaxel Versus Docetaxel Alone In Patients With Recurrent Epithelial Ovarian, Fallopian Tube And Primary Peritoneal Cancer |
| HIC 0703002472 Peter Marks M.D.;Ph.D. A Phase I Clinical Trial of Vorinostat in Combination with Decitabine in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
| HIC 0506000158 Francine Foss M.D. A Phase I Dose Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low Grade or Intermediate Grade B-Cell Lymphoma |